SUMMARY In a multicentre, prospective, randomised, placebo controlled study of 55 patients with histories of genital warts for at least one year, a four week course of inosine pranobex 3 g a day improved the clinical response to conventional treatment (primarily podophyllin or trichloroacetic (now called trichlorethanoic) acid).
Several treatments are available for managing patients with genital warts. They include the topical application of podophyllin' or trichloroacetic (now called trichlorethanoic) acid, cryotherapy,2 electrocautery,2 or carbon dioxide laser. None of these methods of treatment, however, is uniformly successful.
The persistence of genital warts may be associated with a defective immune response.34 Immunomodulating agents have been evaluated in patients with genital warts. Several studies have shown that inosine pranobex is effective in patients with human papillomavirus infection of the genital areas.`' Mohanty and Scott reported that the best response was obtained when inosine pranobex was used as an adjunct to more conventional treatment regimens, such as podophyllin. 5 All the studies reported to date can be criticised for their design, as none was double blind or incorporated a placebo treatment group. We report here a prospective, multicentre, double blind, placebo controlled study conducted to assess whether inosine pranobex improved the efficacy of conventional treatment of patients with genital warts. Accepted for publication 8 April 1988 Patients, materials, and methods
We conducted the study at five centres in the genitourinary medicine departments of hospitals in the United Kingdom. As one centre served patients at three hospitals, we saw patients at seven hospitals. We studied men and women aged over 18 who had anogenital warts and histories of genital warts for at least one year. We excluded homosexual men with perianal warts; women who were pregnant, breast feeding, or not using adequate contraception; and patients with hyperuricaemia or a history of gout, or who were receiving immunosuppressive or cytotoxic treatment. Other concurrent genitourinary diseases were treated before entry into the study. Patients gave informed consent before participating in the study.
The conventional treatment used was that used routinely in the departments concerned. In addition, patients were randomly selected to receive a 28 day course of inosine pranobex 1 g three times a day or an indistinguishable placebo (lactose) medication. Separate randomisation lists were used for men and women. The code was broken centrally by Leo Laboratories.
Patients were scheduled to be seen after being treated for two and four weeks and at further follow up eight and 12 weeks after entering the study. At each clinic attendance the following data were recorded: the deteriorated. Secondly, we analysed only the 27 patients who attended all of the follow up visits. Table 1 shows the demographic data of all patients.
PATIENTS ATTENDING AT LEAST ONE FOLLOW UP VISIT
General response to treatment Table 2 shows the general response to treatment. More patients receiving inosine pranobex than placebo showed an improvement at all the follow up visits, but this was only significant (p < 005) for much inproved patients four weeks after treatment (8/22 v 2/24).
Number of warts present Differences were also seen between the two treatment groups in relation to the reduction in the number of warts present. The number of patients given inosine pranobex with fewer warts varied from 7/22 at week 2 to 14/18 at week 12. Corresponding figures for patients receiving placebo were 7/25 at week 2 and 7/15 at week 8.
Extent oflesions
Reduction in the extent of lesions was also greater at all assessments of patients given inosine pranobex than in those given placebo. Significantly (p < 0.05) more patients given inosine pranobex than placebo had a reduction both at the end ofthe treatment (10/22 v 3/25) and on completion of follow up (14/18 v 6/18).
Development ofnew lesions Similar numbers of patients in the two treatment groups developed new lesions during both treatment and follow up. Of the 51 patients analysed 27 attended all four follow up visits (table 1) . Fourteen of them took inosine pranobex, and placebo tablets were given to 13. The two treatment groups were well matched, although there was a tendency for the placebo group to contain more patients with minimal lesions.
General responses to treatment Table 3 shows that more patients given inosine pranobex than placebo responded, although the difference was not significant. At the end of the study, 11 of the 14 patients receiving active treatment had responded, compared with eight out ofthe 13 receiving placebo. Complete cures were achieved in five patients receiving active treatment and three receiving placebo.
Number ofwarts present Conventional treatment supplemented by inosine pranobex had a significant effect in completely eradicating the warts by the end of the study period (5/14 v 3/13; p < 0.05). The number of patients who had fewer warts by the end of the study was greater in those receiving active treatment (10/14) than placebo (7/13).
Extent oflesions A significant reduction in the extent of lesions at the end of the study compared with the classifications on entry was seen only in patients receiving inosine pranobex (p = 0 05). Lesion extent was reduced in 11 receiving inosine pranobex and five receiving placebo.
Development ofnew lesions
New lesions developed during the study in six out of the 14 patients taking inosine pranobex compared with 11 out of the 13 taking placebo. This difference was not significant.
ADVERSE EFFECTS
Adverse effects were reported by only two patients, one in each treatment group. A woman taking inosine pranobex experienced nausea and stopped treatment as there was also the possibility that she might be pregnant, though subsequent tests did not confirm the pregnancy. A woman taking the placebo tablets
